Emma Walmsley will succeed Andrew Witty next year and become the seventh female chief executive in the FTSE 100.
GSK today announced that Emma Walmsley, currently Chief Executive Officer of GSK’s Consumer Healthcare division, has been appointed GSK CEO Designate and will succeed Andrew Witty when he retires on March 31, 2017. Walmlsey will join the GSK Board of Directors from January 1, 2017. She has been a member of GSK’s Corporate Executive Team since 2011, joining the company in 2010 from L’Oreal where she held a variety of marketing and general management roles in the UK, Europe and USA. From 2007 she was based in Shanghai as General Manager, Consumer Products for L’Oreal China. The appointment sees Walmsley, 47, become the seventh female chief executive in the FTSE 100, The Telegraph reported, and makes her "arguably the most powerful female boss in the index".
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.